Results 31 to 40 of about 68,738 (313)

An Immunological Glance on Pancreatic Ductal Adenocarcinoma [PDF]

International Journal of Molecular Sciences, 2020
Pancreatic ductal adenocarcinoma (PDAC) has still a dismal prognosis. Different factors such as mutational landscape, intra- and intertumoral heterogeneity, stroma, and immune cells impact carcinogenesis of PDAC associated with an immunosuppressive microenvironment. Different cell types with partly opposing roles contribute to this milieu.
Michael Karl Melzer, Frank Arnold, Katja Stifter, Friedemann Zengerling, Ninel Azoitei, Thomas Seufferlein, Christian Bolenz, Alexander Kleger   +7 more
openaire   +2 more sources

A case report of a collision tumor composed of pancreatic ductal adenocarcinoma and peri-pancreatic mucosa-associated lymphoid tissue lymphoma

World Journal of Surgical Oncology, 2023
Background Collision tumors are composed of two distinct tumor components. Collision tumors composed of pancreatic ductal adenocarcinoma and malignant lymphoma occurring in the pancreas have not been previously described in the scientific literature.
Ryuji Hirai, Ken-ichi Omae, Mitsuko Yodoya, Syunji Fujie, Masayoshi Fujii, Kazuma Iwata, Kentaro Imanishi, Eisuke Kurihara, Kazuhiro Yoshida, Masaru Jida, Kazuyasu Kobayashi, Yoshiaki Kanaya, Syuichiro Maruyama   +12 more
doaj   +1 more source

Loss of BAP1 Expression Is Very Rare in Pancreatic Ductal Adenocarcinoma. [PDF]

PLoS ONE, 2016
BACKGROUND:Pancreatic cancer is both common and highly lethal and therefore new biomarkers or potential targets for treatment are needed. Loss of BRCA associated protein-1 (BAP1) expression has been found in up to a quarter of intrahepatic ...
Michael Tayao, Juliana Andrici, Mahtab Farzin, Adele Clarkson, Loretta Sioson, Nicole Watson, Terence C Chua, Tamara Sztynda, Jaswinder S Samra, Anthony J Gill   +9 more
doaj   +1 more source

Hypoxia induces oncogene yes-associated protein 1 nuclear translocation to promote pancreatic ductal adenocarcinoma invasion via epithelial–mesenchymal transition

Tumor Biology, 2017
Pancreatic ductal adenocarcinoma is one of the most lethal cancers. The Hippo pathway is involved in tumorigenesis and remodeling of tumor microenvironments.
Honglong Wei, Zongzhen Xu, Feng Liu, Fuhai Wang, Xin Wang, Xueying Sun, Jie Li   +6 more
doaj   +1 more source

Effect of miR-184 on Proliferation and Apoptosis of Pancreatic Ductal Adenocarcinoma and Its Mechanism

Technology in Cancer Research & Treatment, 2020
Objective: Previous studies have shown that abnormal expression of microRNA-184 leads to a variety of cancers, including pancreatic ductal adenocarcinoma, suggesting microRNA-184 as a new treatment target for pancreatic ductal adenocarcinoma.
Shentao Li MBBS, He Li MD, PhD, Weiwei Ge PhD, Kai Song MM, Chunyu Yuan MM, Ran Yin MBBS   +5 more
doaj   +1 more source

Targeting mTOR in Pancreatic Ductal Adenocarcinoma [PDF]

Frontiers in Oncology, 2016
Treatment options for advanced pancreatic ductal adenocarcinoma (PDAC) are limited; however, new therapies targeting specific tumor-related molecular characteristics may help certain patient cohorts. Emerging preclinical data have shown that inhibition of mammalian target of rapamycin (mTOR) in specific KRAS-dependent PDAC subtypes leads to inhibition ...
Sentia eIriana, Shahzad eAhmed, Jun eGong, Jun eGong, Alagappan Anand Annamalai, Richard eTuli, Andrew Eugene Hendifar   +6 more
openaire   +6 more sources

Expression and clinical significance of placenta-specific 1 in pancreatic ductal adenocarcinoma

Tumor Biology, 2017
The limited efficacy of conventional therapies for pancreatic ductal adenocarcinoma has led to the growing interest for identifying potential antigenic targets for immunotherapy.
Yin Yin, Xu Zhu, Shanshan Huang, Jiawei Zheng, Mengyun Zhang, Wencui Kong, Qun Chen, Yan Zhang, Xiong Chen, Kerong Lin, Xuenong Ouyang   +10 more
doaj   +1 more source

The induction of peripheral trained immunity in the pancreas incites anti-tumor activity to control pancreatic cancer progression

Nature Communications, 2022
The advent of immunotherapy has revolutionised cancer therapeutics, but its application in the context of pancreatic ductal adenocarcinoma has been limited.
Anne E. Geller, Rejeena Shrestha, Matthew R. Woeste, Haixun Guo, Xiaoling Hu, Chuanlin Ding, Kalina Andreeva, Julia H. Chariker, Mingqian Zhou, David Tieri, Corey T. Watson, Robert A. Mitchell, Huang-ge Zhang, Yan Li, Robert C. G. Martin II, Eric C. Rouchka, Jun Yan   +16 more
doaj   +1 more source

MiR-590 Suppresses Proliferation and Induces Apoptosis in Pancreatic Cancer by Targeting High Mobility Group A2

Technology in Cancer Research & Treatment, 2020
Background: Pancreatic ductal adenocarcinoma is a common malignancy with high morbidity. MicroRNAs have been demonstrated to be critical posttranscriptional regulators in tumorigenesis.
Ya-Dong Wang MD, Jia-Ding Mao PhD, Jun-Feng Wang MD, Mao-Qi Xu MD   +3 more
doaj   +1 more source

Pancreatic Ductal Adenocarcinoma Associated with Autoimmune Pancreatitis [PDF]

Case Reports in Gastroenterology, 2011
Autoimmune pancreatitis (AIP), in contrast to other benign chronic pancreatic diseases, can be cured with immunosuppressant drugs, thus the differentiation of AIP from pancreatic cancer is of particular interest in clinical practice. There is the possibility that some patients with AIP may develop pancreatic cancer, and this possibility contributes to ...
Pezzilli R, Vecchiarelli S, Di Marco MC, Serra C, SANTINI, DAVIDE, Calculli L, FABBRI, DARIO, Rojas Mena B, Imbrogno A, Source Pancreas Unit Department of Digestive Diseases and Internal Medicine University of Bologna Bologna Italy.   +9 more
openaire   +4 more sources